Advice

in the absence of a submission from the holder of the marketing authorisation:

vandetanib (Caprelsa®) is not recommended for use within NHS Scotland.

Indication under review: treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHS Scotland.
 

Download detailed advice39KB (PDF)

Download

Medicine details

Medicine name:
vandetanib (Caprelsa)
SMC ID:
797/12
Indication:
Treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
11 June 2012